Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Filings indexed 259 across all filing types
Latest filing 2024-06-12 Declaration of Voting R…
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Prime Medicine, Inc. dated June 12, 2024. It reports on the outcomes of the company's 2024 annual meeting of stockholders, including voting results on director elections, approval of a certificate of amendment, and ratification of the independent auditor. The document includes detailed voting results and descriptions of the proposals voted on. This type of filing is a current report disclosing material events or corporate changes, specifically shareholder voting results from an annual meeting. It is not the annual report itself, nor a proxy statement, but a report of voting results. Therefore, the filing type corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7636 characters) and content confirm it is not merely an announcement of a report but contains substantive voting results data. Confidence is high due to clear identification of voting results and SEC Form 8-K context.
2024-06-12 English
FORM 4
Director's Dealing
2024-06-07 English
FORM 4
Director's Dealing
2024-05-21 English
FORM 4
Director's Dealing
2024-05-21 English
FORM 4
Director's Dealing
2024-05-21 English
DEFA14A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, containing amendments to the company's bylaws and corporate governance updates. It includes a detailed description of changes to the bylaws and references the filing of the amended bylaws as an exhibit. The document is not a full annual or quarterly report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement but rather a regulatory filing reporting governance changes. The presence of detailed governance amendments and the nature of the filing align best with the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories. The document length and content confirm it is not a brief announcement or a proxy statement itself but a current report with governance updates.
2024-05-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.